NEW YORK (360Dx) – Immunovia said that the NYU School of Medicine has joined PanFAM-1, a prospective study investigating early diagnosis in high-risk individuals with familial pancreatic cancer. The study is designed to validate Immunovia’s blood test, IMMray PanCan-d, and will analyze more than 1,000 individuals over three years across sites in the US and Europe.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.